Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandro Villagra

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Translational Oncology|July 12, 2020
CpG-coated prussian blue nanoparticles-based photothermal therapy combined with anti-CTLA-4 immune checkpoint blockade triggers a robust abscopal effect against neuroblastomaJuliana Cano-Mejia, Anshi Shukla, Debbie K Ledezma, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 2, 2016
Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell MalignanciesJohn Powers, Maritza Lienlaf, Patricio Perez-Villarroel, et al.
Cancer Immunology Research|August 23, 2015
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 BlockadeDavid M Woods, Andressa L Sodré, Alejandro Villagra, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 2, 2016
Functional Analysis of Histone Deacetylase 11 (HDAC11)Jie Chen, Eva Sahakian, John Powers, et al.
Journal of Medicinal Chemistry|September 27, 2012
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growthJoel A Bergman, Karrune Woan, Patricio Perez-Villarroel, et al.
Current Pharmaceutical Design|January 30, 2010
Circumventing immune tolerance through epigenetic modificationJason A Dubovsky, Alejandro Villagra, John J Powers, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma ModelsMaurício T Tavares, Sida Shen, Tessa Knox, et al.
Clinical Epigenetics|January 17, 2019
Epigenetic therapy for ovarian cancer: promise and progressSara Moufarrij, Monica Dandapani, Elisa Arthofer, et al.
Plos One|March 17, 2025
Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigenGargi Das, Jakub Ptacek, Jana Campbell, et al.
Molecular and Cellular Biology|April 7, 2010
The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functionsZhigang Yuan, Alejandro Villagra, Lirong Peng, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Translational Oncology|July 12, 2020
CpG-coated prussian blue nanoparticles-based photothermal therapy combined with anti-CTLA-4 immune checkpoint blockade triggers a robust abscopal effect against neuroblastomaJuliana Cano-Mejia, Anshi Shukla, Debbie K Ledezma, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 2, 2016
Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell MalignanciesJohn Powers, Maritza Lienlaf, Patricio Perez-Villarroel, et al.
Cancer Immunology Research|August 23, 2015
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 BlockadeDavid M Woods, Andressa L Sodré, Alejandro Villagra, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 2, 2016
Functional Analysis of Histone Deacetylase 11 (HDAC11)Jie Chen, Eva Sahakian, John Powers, et al.
Journal of Medicinal Chemistry|September 27, 2012
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growthJoel A Bergman, Karrune Woan, Patricio Perez-Villarroel, et al.
Current Pharmaceutical Design|January 30, 2010
Circumventing immune tolerance through epigenetic modificationJason A Dubovsky, Alejandro Villagra, John J Powers, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma ModelsMaurício T Tavares, Sida Shen, Tessa Knox, et al.
Clinical Epigenetics|January 17, 2019
Epigenetic therapy for ovarian cancer: promise and progressSara Moufarrij, Monica Dandapani, Elisa Arthofer, et al.
Plos One|March 17, 2025
Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigenGargi Das, Jakub Ptacek, Jana Campbell, et al.
Molecular and Cellular Biology|April 7, 2010
The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functionsZhigang Yuan, Alejandro Villagra, Lirong Peng, et al.
Pageof 6